Publication Year

Haws LC, DeVito MJ, Walker NJ, Harris MA, Tachovsky JA, Birnbaum LS, Farland WH, Wikoff DS. 2011. Development of a consensus-based weighting framework for evaluating estimates of relative potency for dioxin-like compounds that includes consideration of data from human cells. Presented at Dioxin 2011, August 21-25, Brussels, Belgium.

Semeraro A, Patriarca M, Taylor A, Henderson R, Bates H. 2011. Nickel kinetics after oral exposure: Urinary excretion. IUPAC 4th International Symposium for Trace Elements in Food.

Haws LC, Fitzgerald L, Burkhalter B, Harris M, Wikoff DS. 2011. Assessment of the US EPA’s proposed toxicological values for TCDD for regulation of dioxin-like compounds in foods: Bridging the science divide in a global market. Presented at Dioxin 2011, August 21-25, Brussels, Belgium.

Gujral JS, Proctor DM, Su SH, and Fedoruk JM. 2011. Water adherence factors for human skin. Risk Analysis 31(8):1271-1280.

Rowlands JC, Urban J, Wikoff DS, Budinsky R. 2011. The presence and estimated functional effect of single nucleotide polymorphisms at the AIP, ARNT, HSP90AA1, AND HSP90AB1 loci in the human population. Presented at Dioxin 2011, August 21-25, Brussels, Belgium.

Miletich J, Eich G, Grampp G, and Mounho B. 2011. Guiding principles for a global “patients first” standard. mAbs 3(3):318-325.

Thomas RS, Rowlands JC, Budinsky RA, Thompson CM, Urban JD. Dombkowski, A. 2011. Genomic approaches for relative potency assessment. Presented at Dioxin 2011, August 21-25, Brussels, Belgium.

Rowlands JC, Urban JD, Wikoff DS, Budinsky RA. 2011. An evaluation of single nucleotide polymorphisms in the human aryl hydrocarbon receptor-interacting protein (AIP) gene. Drug Metab Pharmacokinet 26(4):431-439.

Wikoff DS, Thompson C, Walker N, DeVito M, Harris M, Birnbaum L, Haws L. 2011. Derivation of relative potency estimates using benchmark dose modeling: A case study with TCDF. Presented at Dioxin 2011, August 21-25, Brussels, Belgium.

Sheehan PJ, Brorby GP, Berman DW, Bogen KT, Holm SE. 2011. Chamber for testing asbestos-containing products:  Validation and testing of a re-created chrysotile-containing joint compound.  Ann Occup Hyg 55(7):797-809.